India, Aug. 10 -- Shares of Aligos Therapeutics, Inc. (ALGS) are up 26.99% today. The company recently provided an update on its pipeline and reported its second-quarter 2026 financial results, with investors focusing on progress in its chronic hepatitis B programs and strengthened non-dilutive funding.
-- Recent Business & Pipeline Updates:
Aligos received Breakthrough Therapy Designation in China for pevifoscorvir sodium for chronic hepatitis B virus (HBV) infection.
The Phase 2 B-SUPREME study of pevifoscorvir sodium has completed enrollment, with topline data from both HBeAg+ and HBeAg- cohorts expected in late Q3 2027.
Aligos received a $25 million upfront payment from Amoytop under an exclusive Greater China licensing agreement fo...